GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » EV-to-EBITDA

AbCellera Biologics (STU:8QQ) EV-to-EBITDA : -1.13 (As of Nov. 10, 2024)


View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AbCellera Biologics's enterprise value is €209.13 Mil. AbCellera Biologics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was €-185.54 Mil. Therefore, AbCellera Biologics's EV-to-EBITDA for today is -1.13.

The historical rank and industry rank for AbCellera Biologics's EV-to-EBITDA or its related term are showing as below:

STU:8QQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -50.05   Med: 6.53   Max: 2202.26
Current: -1.12

During the past 6 years, the highest EV-to-EBITDA of AbCellera Biologics was 2202.26. The lowest was -50.05. And the median was 6.53.

STU:8QQ's EV-to-EBITDA is ranked worse than
100% of 445 companies
in the Biotechnology industry
Industry Median: 10.21 vs STU:8QQ: -1.12

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-11-10), AbCellera Biologics's stock price is €2.489. AbCellera Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.559. Therefore, AbCellera Biologics's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


AbCellera Biologics EV-to-EBITDA Historical Data

The historical data trend for AbCellera Biologics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics EV-to-EBITDA Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - 60.46 14.08 8.08 -5.09

AbCellera Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.94 -5.09 -3.86 -1.40 -0.97

Competitive Comparison of AbCellera Biologics's EV-to-EBITDA

For the Biotechnology subindustry, AbCellera Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbCellera Biologics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's EV-to-EBITDA falls into.



AbCellera Biologics EV-to-EBITDA Calculation

AbCellera Biologics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=209.133/-185.535
=-1.13

AbCellera Biologics's current Enterprise Value is €209.13 Mil.
AbCellera Biologics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-185.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbCellera Biologics  (STU:8QQ) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

AbCellera Biologics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.489/-0.559
=At Loss

AbCellera Biologics's share price for today is €2.489.
AbCellera Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.559.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


AbCellera Biologics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


AbCellera Biologics Business Description

Traded in Other Exchanges
Address
2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics Headlines

No Headlines